Novo Nordisk A S annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S R&D Spending Growth & History (NVO)
Novo Nordisk A S's r&d spending was kr52.04B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr52.04B | kr3.98B | +8.27% |
| 2024 | 2024-12-31 | kr48.06B | kr15.62B | +48.14% |
| 2023 | 2023-12-31 | kr32.44B | kr8.40B | +34.91% |
| 2022 | 2022-12-31 | kr24.05B | kr6.28B | +35.31% |
| 2021 | 2021-12-31 | kr17.77B | kr2.31B | +14.94% |
| 2020 | 2020-12-31 | kr15.46B | kr1.24B | +8.73% |
| 2019 | 2019-12-31 | kr14.22B | — | — |
Novo Nordisk A S quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr17.79B | kr6.10B | +52.16% |
| Q1 2026 | 2026-03-31 | kr10.28B | — | — |
| Q4 2025 | 2025-12-31 | kr14.65B | — | — |
| Q3 2025 | 2025-09-30 | kr15.39B | — | — |
| Q2 2025 | 2025-06-30 | kr11.69B | — | — |
Novo Nordisk A S r&d spending trends
Over the last five fiscal years, Novo Nordisk A S's r&d spending increased from kr15.46B to kr52.04B, a change of kr36.58B. The latest reported quarter, Q2 2026, shows kr17.79B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...